I-FIGS Feasibility Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-23

Study Completion Date

2024-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Removal of part of the liver (resection) is performed as a treatment for some cancers in the liver. To achieve the best possible outcomes, it is important that the cancer is removed completely (R0 resection) (1). Up to 30-50% patients develop recurrence within 2 years of surgery which could be due to incomplete removal of the cancer (2). Various techniques are used by the surgeons to identify the cancer tissue from the normal liver during the surgery so that it can be removed completely. These include examining with the naked eye, having a feel of the tumour, and performing an ultrasound scan. Even with these techniques it is difficult to identify the exact extent of the cancer. Also, the interpretation of the ultrasound scan can be subjective (3). A robust, objective, real-time navigation technique is required which can differentiate cancer from normal tissue.

Indocyanine green (ICG) is a dye which when given through the veins, is taken up and retained by cancer cells in the liver and they appear as fluorescent areas as compared to normal liver which appears dark. This principle can be used to identify the cancerous tissue accurately during the surgery and remove it completely (Indocyanine green Fluorescence Image-Guided Surgery: I-FIGS). It can also potentially detect additional tumours which were not identified before the surgery or during the surgery with standard techniques (4,5). However, there is a lack of good quality evidence on the usefulness of I-FIGS in liver surgery, so this needs to be tested in a large group of patients having liver surgery before any recommendations can be made.

Research Aim:

This initial study aims to assess whether a larger trial evaluating the role of I-FIGS in complete removal of the cancer tissue is feasible. Investigators will assess if patients are willing to take part in the study and whether they can gather relevant clinical outcome data from them all. Investigators will also gather patients' views about this novel technique and participating in the study.

Design and methods:

This study will involve 40 patients having planned liver surgery for liver tumour/s recruited from University Hospitals, Plymouth. Patients will be randomly allocated to have I-FIGS plus standard surgery or standard liver surgery alone. Patients in the I-FIGS group will have ICG injection 2-4 hrs prior to surgery (0.03-0.05mg/kg dose) on the day of surgery. The surgical planning will be carried out as per the standard approach using the naked eye and intra-operative ultrasound examination. Once this is all recorded, ICG cameras will be switched on, and the additional findings and change to surgical plan will be noted. Focus groups will explore participants experiences of being in the study. This will inform the design of the future larger trial.

Patient public involvement:

Investigators have involved patients who have had or are having liver surgery in the development of the study. Their views on the technique, trial procedures and outcome measures have been incorporated. They will continue to be involved and advise on the study.

Dissemination:

Results will be available via research journals and conferences.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy

NCT02822716

Hepatic Malignant Tumors Pancreatic Cancer

TERMINATED NA

Evaluation of Image-Guided Liver Surgical System for Resection of Liver Cancer

NCT00782886

Liver Cancer

COMPLETED

Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence

NCT02391207

Secondary Malignant Neoplasm of Liver

COMPLETED

Vascular Invasion Signatures in cfDNA Support Re-staging of Liver Cancer

NCT05540925

Carcinoma, Hepatocellular Hepatocellular Cancer Liver Cancer

COMPLETED

Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients

NCT01914289

Intrahepatic Cholangiocarcinoma

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cancer Hepatocellular Carcinoma Liver Metastasis Colon Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Feasibility Randomized Controlled Study

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group (Standard liver surgery)

In this group, tumour/s, resection margin identification, and the type and number of liver resections will be based on naked eye examination, palpation, and intraoperative ultrasound. All the intra-operative findings will be recorded on a pre-designed proforma, and these details include the type of surgical approach (open, laparoscopic, and hand-assisted), if it is an open operation the type of incision, the location, number and size of tumour/s, relationship of the tumour/s to inflow and outflow of the liver, duration of surgery, and estimated blood loss. Post-operatively histology of the resected specimen including resection margin status will be recorded.

Group Type ACTIVE_COMPARATOR

Standard Liver Surgery

Intervention Type PROCEDURE

Standard liver surgery using naked eye examination +/- palpation and intra-operative ultrasound scan (IOUS) examination to identify and remove liver tumours

Intervention Group (I-FIGS)

Patients will receive intravenous indocyanine green(ICG) injection (0.03-0.05mg/kg) 2-4 hours before surgery. ICG comes in crystal form in 25mg dose. It will be diluted with 25ml of water, and the required dose as per the weight of the patient will be prepared freshly and given at least 2-4 hours before surgery. The surgical planning will be carried out as per the standard approach using the naked eye and IOUS. As for standard surgery, all intra-operative findings will be recorded on the proforma that contains the details that need to be collected. Once this is all recorded, ICG cameras will be switched on, and the additional findings (additional lesions detected, additional resections carried out) and change to surgical plan (change to the line of parenchymal transection) will be noted. Post-operatively histology of the resected specimen including resection margin status will be recorded.

Group Type EXPERIMENTAL

Standard Liver Surgery

Intervention Type PROCEDURE

Standard liver surgery using naked eye examination +/- palpation and intra-operative ultrasound scan (IOUS) examination to identify and remove liver tumours

Indocyanine Fluorescent Image Guided Surgery (I-FIGS)

Intervention Type DIAGNOSTIC_TEST

Use of I-FIGS in accurate identification of tumours and their margins

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard Liver Surgery

Standard liver surgery using naked eye examination +/- palpation and intra-operative ultrasound scan (IOUS) examination to identify and remove liver tumours

Intervention Type PROCEDURE

Indocyanine Fluorescent Image Guided Surgery (I-FIGS)

Use of I-FIGS in accurate identification of tumours and their margins

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• All adult patients (\>16 years) requiring elective open/laparoscopic liver resection/s for liver metastases, primary hepatocellular and peripheral cholangiocarcinoma will be included in the study.

Exclusion Criteria

* Patients allergic to iodine/contrast or shellfish
* Patients unable to consent to the study
* Patients with suspected liver adenomas and biliary cystadenomas
* Patients with suspected hilar cholangiocarcinoma
* Patients requiring emergency liver surgery
* Pregnant patients

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No